Goldman Sachs Group set a €114.00 ($132.56) price target on MorphoSys (ETR:MOR) in a research note released on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Several other equities research analysts have also recently weighed in on the stock. Berenberg Bank set a €108.00 ($125.58) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Wednesday. Deutsche Bank set a €125.00 ($145.35) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Thursday, May 9th. Independent Research set a €96.00 ($111.63) price target on shares of MorphoSys and gave the stock a neutral rating in a research report on Thursday, May 9th. JPMorgan Chase & Co. set a €120.00 ($139.53) price target on shares of MorphoSys and gave the stock a buy rating in a research report on Wednesday, May 8th. Finally, Royal Bank of Canada set a €65.00 ($75.58) price target on shares of MorphoSys and gave the stock a sell rating in a research report on Thursday, March 14th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company. The stock currently has an average rating of Hold and an average target price of €100.78 ($117.18).
MOR traded down €0.25 ($0.29) during trading hours on Friday, hitting €93.25 ($108.43). The company’s stock had a trading volume of 193,141 shares, compared to its average volume of 153,687. MorphoSys has a 12 month low of €76.45 ($88.90) and a 12 month high of €124.90 ($145.23). The stock has a market capitalization of $2.94 billion and a PE ratio of -50.16. The company has a debt-to-equity ratio of 8.65, a quick ratio of 7.53 and a current ratio of 7.75.
MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma.
Recommended Story: Fibonacci Channel
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.